|
|
![horizontal rule](https://webarchive.library.unt.edu/web/20090511194938im_/http://www.fda.gov/graphics/blkpixel.gif) |
Congressional
Testimony
|
|
![](https://webarchive.library.unt.edu/web/20090511194938im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
|
|
|
|
![](https://webarchive.library.unt.edu/web/20090511194938im_/http://www.fda.gov/graphics/dot_clear.gif) |
- November 18, 2004
Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs
Subject: FDA's Ongoing Efforts to Ensure the Safety, Effectiveness, and Availability of Influenza and Other Vaccines
Before: Before the Committee on Energy and Commerce,
United States House of Representatives
- November 18, 2004
Sandra Kweder, M.D.,
Deputy Director, Office of New Drugs
Subject: Vioxx
and Drug Safety
Before: Committee on Finance,
United States Senate
- November 17, 2004
Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs
Subject: FDA's Ongoing Efforts to Ensure the Safety, Effectiveness, and Availability of Influenza and Other Vaccines
Before: Before the Committee on Government
Reform,
United States House of Representatives
- November 16, 2004
Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner
of Food and Drugs
Subject: FDA's
Ongoing Efforts to Ensure the Safety, Effectiveness, and Availability
of Influenza and Other Vaccines
Before: Special Committee on Aging
United States Senate
- October 5, 2004
William Egan, Ph.D., Acting Director, Office of Vaccines Research
and Review
Subject: Regulation and oversight of vaccines in the United
States
Before: Subcommittee on Labor, Health and
Human Services, Education and Related Agencies
- September 23, 2004
Robert Temple, M.D.,
Director, Office of Medical Policy, Center for Drug Evaulation and Research
Subject: Anti-depressant
drugs for use in pediatric populations
Before: Subcommittee on Oversight and Investigations, Committee
on Energy and Commerce
- September 9, 2004
Janet Woodcock, M.D., Acting Deputy Commissioner for Operations
Subject: Pediatric Clinical Trials for Antidepressant Drug Products
Before: Subcommittee on Oversight and Investigations, Committee on Energy and Commerce
- September 8, 2004
William Egan, Ph.D., Office of Vaccines Research and Review, Center for Biologics Evaluation and Research
Subject: Thimerosal in Vaccines
Before: Subcommittee on Human Rights and Wellness,
Committee on Government Reform
- July 22, 2004
John M. Taylor, III, Associate Commissioner for Regulatory
Affairs
Subject: Importation
of Prescription Drugs
Before: Committee
on Governmental Affairs
- July 14, 2004
William K. Hubbard, Associate Commissioner for Policy
and Planning
Subject: Importation
of Prescription Drugs
Before: Committee on the Judiciary, United States
Senate
- June 25, 2004
Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner
of Food and Drugs
Subject: Implementation of the Food Security Provisions
of the Public Health Security and Bioterrorism Preparedness
and Response Act
Before: Committee on Energy and Commerce
- June 23, 2004
Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner
of Food and Drugs
Subject: The Law of Biologic Medicine
Before: The Committee on the Judiciary
- June 8, 2004
Robert E. Brackett, PH.D. Director
Center for Food Safety and Applied Nutrition
Subject: Dietary Supplement Safety
Act: How is FDA Doing 10 Years Later
Before: Committee on Governmental Affairs
- June 3, 2004
Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner
of Food and Drugs
Subject: HHS’s
Role in Combating the Nation’s Obesity Epidemic
Before: The Committee on Government Reform
- June 3, 2004
Lynn C. Swann, Chairman,
President’s Council on Physical Fitness and Sports,
Office of Public Health and Science
Subject: Combating
the Obesity Epidemic
Before: The Committee on Government
Reform
- May 20, 2004
John M. Taylor, Associate Commissioner for Regulatory Affairs
Subject: Imported
Drugs
Before: Committee on Health Education, Labor
and Pensions
- May 18, 2004
Emanuel F. Petricoin III, Ph.D. Senior Investigator,
Office of Cell, Tissue and Gene Therapies
Subject: Conflict
of Interest
Before: The House Investigation and Oversight
Subcommittee
- May 18, 2004
Statement for the Record
Subject: Comments
on Ethics
Before: Subcommittee on Oversight and Investigations
- May 18, 2004
Steven Gutman, M.D., Director, Office of In
Vitro Diagnostic Device Evaluation and Safety
Subject: Adaltis
Labotech device
Before: Committee on Government Reform,
U.S. House of Representatives
- May 13, 2004
Richard Pazdur, M.D., Director, Division
of Oncology Drug Products
Subject: Harnessing
Science: Advancing Care By AcceleratingThe Rate of Cancer
Clinical Trial Participation
Before: Committee on Government Reform,
U.S. House of Representatives
- April 27, 2004
William K. Hubbard, Associate Commissioner for Policy
and Planning
Subject: Importation
of Prescription Drugs
Before: Subcommittee on Healthcare and Subcommittee
on International Trade, Committee on Finance
- April 1, 2004
Robert J. Meyer, M.D., Director,
Office of Drug Evaluation II, Center for Drug Evaluation,
and Research
Subject: FDA's
Drug Approval Process
Before: Subcommitte on Criminal Justice, Drug Policy
and Human Resources, Committee on Government Reform.
- March 30, 2004
Robert E. Bracket, Ph.D., Director,
Center for Food Safety and Applied Nutrition
Subject: Single Food Agency
Before: Committee on Government Reform, Subcommittee
on Civil Service and Agency Organization, United States House
of Representatives.
- March 23, 2004
Robert E. Brackett, Ph.D., Director,
Center for Food Safety and Applied Nutrition
Subject: Ten
Years After the Implementation of DSHEA: The Status of Dietary
Supplements in the United States.
Before: Committee on Government Reform, Subcommittee on Human Rights and
Wellness, United States House of Representatives.
- March 18, 2004
William K. Hubbard, Associate Commissioner
for Policy and Planning
Subject: Internet
Drug Sales
Before: Committee on Government Reform, House of Representatives.
- March 11, 2004
Daniel G. Schultz, M.D., Director,
Office of Device Evaluation, Center for Devices and Radiological
Health
Subject: FDA’s
implementation of Public Law (P.L.) 106-554 with respect to
the labeling of condoms
Before: Subcommittee on Criminal
Justice, Drug Policy, and Human Resources Committee on Government
Reform.
-
March 11, 2004
Dr. Mark B. McClellan, Commissioner
of Food and Drugs
Subject: Cost of Prescription Drugs
Before: Committee on Commerce Science and Transportation United States
Senate
- February 9, 2004
Robert J. Meyer, M.D., Director,
Office of Drug Evaluation II, Center For Drug Evaluation
and Research
Subject: FDA's
Drug Approval Process and Role in Preventing Prescription
Drug Abuse
Before: U.S. House of Representatives, Committee on Government Reform,
Subcommittee on Criminal Justice, Drug Policy and Human Resources.
-
January 27, 2004
Lester M. Crawford, D.V.M.,
Ph.D., Deputy Commissioner of Food and Drugs
Subject: Bovine Spongiform Encephalopathy
(BSE)
Before: Committee on Agriculture, Nutrition and Forestry.
|
![](https://webarchive.library.unt.edu/web/20090511194938im_/http://www.fda.gov/graphics/dot_clear.gif) |
![](https://webarchive.library.unt.edu/web/20090511194938im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
![](https://webarchive.library.unt.edu/web/20090511194938im_/http://www.fda.gov/graphics/dot_clear.gif) |
![](https://webarchive.library.unt.edu/web/20090511194938im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
![](https://webarchive.library.unt.edu/web/20090511194938im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
![](https://webarchive.library.unt.edu/web/20090511194938im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
|
|